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Abstract
Adaptive radiotherapy (ART) strategies systematically monitor variations in target and neighbouring structures to inform treatment-plan modiﬁcation during
radiotherapy. This is necessary because a single plan designed before treatment is insufﬁcient to capture the actual dose delivered to the target and adjacent critical
structures during the course of radiotherapy. Magnetic resonance imaging (MRI) provides superior soft-tissue image contrast over current standard X-ray-based
technologies without additional radiation exposure.With integratedMRI and radiotherapy platforms permittingmotionmonitoring during treatment delivery, it is
possible that adaption can be informed by real-time anatomical imaging. This allows greater treatment accuracy in terms of dose delivered to target with smaller,
individualised treatment margins. The use of functional MRI sequences would permit ART to be informed by imaging biomarkers, so allowing both personalised
geometric and biological adaption. In this review, we discuss ART solutions enabled by MRI guidance and its potential gains for our patients across tumour types.
 2018 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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An electronic literature search was carried out using
PubMed andWeb of Science databases. The ﬁnal search was
carried out in July 2018. Search terms included “radio-
therapy”, “radiotherapy planning”, “adaptive radiotherapy”,
“online adaptive radiotherapy”, “magnetic resonance”,
“MR”, “MR-guided”, “radiotherapy tracking”, and “radio-
therapy gating”. The search was restricted to those pub-
lished in English with preference given to more recent
studies. Selected studies were ﬁrst screened by their title
and/or abstract followed by full article review of relevant
articles. A manual review of the reference list of relevant
studies was also undertaken.Introduction
The target for radiotherapy is dynamic. It varies in posi-
tion, shape, size, and biology over a time frame that extendsAuthor for correspondence: S. Hafeez, Royal Marsden Hospital, Downs
Road, Sutton, Surrey SM2 5PT, UK. Tel.: 0208 661 3467.
E-mail address: shaista.hafeez@icr.ac.uk (S. Hafeez).
https://doi.org/10.1016/j.clon.2018.08.001
0936-6555/ 2018 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Hunt A, et al., Adaptive Radiotherapy
10.1016/j.clon.2018.08.001over seconds, days, and weeks (Figure 1). Reliance on a
single pre-treatment planning computed tomography (CT)
scan to capture this change over the treatment course is
misplaced. Historically, to try and account for this geometric
variation, large margins have been used to create the
planning target volume (PTV) [1e3]. This, however, often
limits dose escalation to tumoricidal levels because of
concerns regarding collateral damage to adjacent normal
structures [4,5].
Accepting that the PTV is a statistical construct to ensure
that dose can be successfully delivered to the tumour, reli-
ably decreasing PTV size is only possible when there is
conﬁdence in target positioning during treatment. Tech-
nologies that have enabled imaging in the treatment room
have allowed gains to be made on this front, so overcoming,
in part, the challenge of hitting an otherwise invisible target
with an invisible beam. Image-guided radiotherapies
(IGRTs), particularly those permitting soft-tissue visual-
isation, such as cone-beam CT (CBCT), prior to treatment
delivery, have already demonstrated step-wise improve-
ment in target coverage. This has been achieved using
smaller margins and a subsequent reduction in integrald. This is an open access article under the CC BY-NC-ND license (http://
Enabled by MRI Guidance, Clinical Oncology (2018), https://doi.org/
Fig 1. Timescales for adaptation and ART solutions implemented .
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for target position such as skin tattoos or bony anatomy [6].
Adaptive radiotherapy (ART) is an umbrella term
encompassing techniques that allow knowledge of patient-
speciﬁc anatomical variations informed by IGRT to feedback
into the plan and dose-delivery optimisation during the
treatment course [7]. This ensures that the planned dose is
delivered as accurately and precisely as possible according
to the anatomy of the day. ART can be implemented broadly
over three timescales (Figure 1): (1) ofﬂine between frac-
tions, (2) online immediately prior to a fraction, and (3) in
real-time during a fraction.
Ofﬂine ART monitors the position of the target during a
limited number of fractions. It addresses systematic
changes to some extent, but also allows opportunity for an
individualised PTV margin to be applied based on acquired
knowledge of the location of volumes of interest and patient
set-up. Although adaptation is not informed by the exact
position of the tumour at each fraction, the applied margins
are often smaller than population derived margin recipes
[8,9]. Online and real-time ART protocols modify the
treatment plan while the patient remains on the couch.
These strategies allow for a patient speciﬁc PTV to be
created because they are informed by the actual change in
anatomy seen for that fraction. As there is greater certainty
to the true position of the tumour, an even smaller “safety”
margin can be considered. The conﬁdence in soft-tissue
targeting at the time of radiotherapy delivery provides an
opportunity to deliver higher radiation doses with tighter
margins. In this review, we discuss ART solutions enabled by
magnetic resonance imaging (MRI) guidance and it poten-
tial gains for our patients.Please cite this article in press as: Hunt A, et al., Adaptive Radiotherapy
10.1016/j.clon.2018.08.001Will MRI-Guided Radiotherapy be the
Ultimate Online IGRT Solution?
The persisting weakest link in the treatment chain for
radiotherapy remains clinician-led target identiﬁcation
[10,11]. Repeated studies have demonstrated that gross
tumour volume (GTV) and organ at risk (OARs) delineation
variability between observers introduces systematic errors,
which are larger than daily set-up uncertainties [12e14].
One of the most important factors responsible for the
observed target variation is adequate imaging [12].
Compared to CT or CBCT, MRI offers superior soft-tissue
deﬁnition with no associated radiation risk [15e17]. As a
result, for many tumours diagnostic MRI improves inter- and
intra-observer delineation consistency [12,18e20]. Observer
variation also improves with the use of standardised guide-
lines, anatomy atlases, and auto-segmentation tools [21].
MRI delineated target volumes are often reported to be
signiﬁcantly different from those contoured on CT. Occa-
sionally, MRI identiﬁes targets larger than on CT because
tumour that otherwise would have been missed is now seen
[20]; however, most commonly, targets are reported to be
smaller when delineated on MRI [18,19,22,23]. The resulting
smaller MRI-derived target improves the therapeutic ratio so
enabling dose escalation. For example, an MRI-delineated
prostate, allows dose escalation of 2e7 Gy while maintain-
ing the same rectal wall dose comparedwith a CT-delineated
prostate [24]. Similarly, in cervical cancer, dose escalation is
possible using an MRI-informed target with an associated
10e20% survival gain seen at 3 years with reduced gastro-
intestinal and urinary late morbidity [25].Enabled by MRI Guidance, Clinical Oncology (2018), https://doi.org/
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‘right’ radiotherapy target, but robust pathological correla-
tion is necessary as the GTV is a factual construct of
macroscopic disease. Only with this information will it be
possible to know how closely the MRI visualised target
represents the ‘true’ pathological target and how closely the
delineated GTV represents actual disease [2]. Without this
knowledge, although ART targets may get progressively
smaller, and dose more conformal, we risk possible in-
creases inmarginal recurrences, undoing all efforts invested
in improving radiotherapy precision and accuracy with this
technology [26,27].
The availability of on-board ‘functional’ MRI sequences
holds promise that geometric adaptation maybe com-
plemented by biological adaptation. For example, diffusion-
weighted imaging (DWI) is a functional imaging technique
dependent on the inhibitory effect of cell membranes to the
random motion of water molecules to generate image
contrast. As tumours usually have greater cellularity than
normal tissue, they demonstrate higher signal intensity, i.e.,
restricted diffusion onMRI. This is reﬂected in the lowmean
apparent diffusion coefﬁcient (ADC) value. This has poten-
tial to provide both qualitative and quantitative informa-
tion. Change in the ADC has been used to identify early
treatment response, and to predict local recurrence
[28e30]. Therefore, on-board DWI could identify early non-
responders who may beneﬁt from change in treatment
approach [31].
The feasibility of biological ART based on functional im-
aging signal change mid-treatment has been shown
possible in a single-arm Phase 2 study [32]. Kong et al., used
2-[18F]-ﬂuoro-2-deoxy-D-glucose positron-emission to-
mography CT (FDG-PET CT) mid-treatment to inform the
volume for dose escalation (up to 80 Gy in 30 factions) in
patients with inoperable stage IIeIII non-small cell lung
cancer [32]. Similarly, DWI signal change during radio-
therapy could be used to inform adaptation and dose
escalation in relevant tumours [29]. Randomised control
studies would be necessary to ensure no adverse impact on
disease control occurred, as the shrinking metabolic target
might inadvertently reduce coverage of macroscopic or
microscopic disease [27].
The challenges of MRI acquisition and planning using an
integrated MRI radiotherapy platform have been addressed
in the accompanying articles in this special edition.ART Techniques
Ofﬂine ART Solutions
Ofﬂine ART aims to correct for the systematic changes to
either the target or OARs identiﬁed by in-room imaging
during the course of treatment. Plan modiﬁcation, however,
takes place ofﬂine often adopting the same workﬂow as the
original plan creation including repeat simulation. This is
currently the commonest approach to accommodate
changes that cannot be corrected by couch shift alone [8,9].Please cite this article in press as: Hunt A, et al., Adaptive Radiotherapy
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tour are seen on CBCT because of weight change or treat-
ment response during conventionally fractioned courses.
These changes trigger the creation of a new plan in an
attempt to improve dosimetry and achieve the planned
prescription for the remaining fractions [33]. Until recently,
this would have required a similar amount of time as
generating the original plan, so limiting the frequency of
adaption but developments in automated contour propa-
gation and automatic plan re-optimisation open the possi-
bility of more frequent plan adjustments [34,35].
When online image guidance informs ofﬂine adaptation,
authors occasionally refer to this approach as ‘hybrid
adaptation’ [17,36]. Hybrid and ofﬂine ART protocols offer
the opportunity for patients to beneﬁt from ART enabled by
MRI guidance without an integrated MRI radiotherapy
system using either a diagnostic MRI scanner, MRI simu-
lator, or a shuttle-based MRI-guided radiotherapy system
(MRI on rails) [37,38].
Although no consensus regarding the threshold to
trigger ofﬂine ART exists, planning studies repeatedly show
that a static patient model created at simulation is often
obsolete and non-representative of the treatment course.
Any adaption, even if implemented at a single time point
during a conventionally fractionated treatment course, de-
livers dosimetric improvement above a single planning scan
[33]. Oh et al., showed that weekly online MRI with ofﬂine
intensity-modulated radiotherapy (IMRT) re-planning us-
ing a 3 mm PTV margin in cervical cancer patients accounts
for intrafraction pelvic organ motion and tumour shrinkage
withmeasurably improved target coveragewhen compared
to no or a single re-plan [17].
In many tumour types, daily imaging offers an advantage
[39e41]. Decreasing the image frequency potentially in-
creases the proportion of fractions associated with signiﬁ-
cant localisation errors. For example, in prostate cancer
radiotherapy, decreasing the imaging frequency from daily
to alternate day imaging, results in step up errors of>5 mm
in 24% of fractions, which increases to approximately 40%
when the set-up error threshold is >3 mm [39].
The logistics of repeated MRI outside the treatment room
could be challenging; however, the feasibility for an ofﬂine
ART protocol, informed by daily out-of-room MRI guidance
has been shown to be possible using a shuttle-based MRI
workﬂow inpelvicmalignancies [38].Median total treatment
time for each fraction, including time for patient positioning,
MRI acquisition, shuttle transfer to treatment suite, patient
repositioning, CBCTacquisition, and IMRTdeliverywasover 1
hour (61 minutes; range 47e99 minutes) [38].
Symptomatic patients are unlikely to tolerate prolonged
immobilisation very well. They are also more likely to have
larger positional inaccuracies between out-of-room MRI
and radiotherapy [38]. The long gap between MRI and
treatment also means intrafractional organ motion un-
certainties persist [13]. So, although ofﬂine/hybrid ap-
proaches may help bridge demands for MRI-enabled ART,
alternative ART approaches are necessary to address both
inter- and intrafraction motion.Enabled by MRI Guidance, Clinical Oncology (2018), https://doi.org/
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Online Adaptive Re-planning
Online adaptive re-planning necessitates a rapid work-
ﬂow that brings together online imaging, image registra-
tion, contour propagation, plan re-optimisation, quality
assurance, and treatment delivery all while the patient is on
the treatment couch (Figure 2) [42].
Monte Carlo dose calculations are recognised as being
the most accurate method for radiotherapy treatment
planning, but until recently they had been constrained by
long computational times precluding their use for rapid
dose calculation. Proposed ways to accelerate Monte Carlo
dose calculations are with graphical processing unit (GPU)
technology, clusters of central processing units (CPUs), or
cloud-based solutions [43e45]. Monte Carlo-based treat-
ment planning systems are also needed to reliably model
dose for any integrated MRI radiotherapy platform where
the beam passes through the magnetic ﬁeld. This is neces-
sary because when the magnetic ﬁeld is orthogonal to the
radiation beam, the trajectories of secondary electrons are
altered owing to the Lorentz force, resulting in high dose
deposition at air-tissue interfaces, and so altering beam
proﬁles than would otherwise be expected [46,47].
In its simplest forms online adaptation involves patient
repositioning by shifting the plan to the relative anatomy
seen on the day. This can be achieved by a simple couch
shift to accommodate the interfraction change with no
additional optimisation of the initial treatment plan [48,49].
This strategy provides only ﬁrst-order correction, as target
rotations, volume and shape change, and the geometric
relationship to surrounding normal structures are not fully
considered [50]. It is arguably more consistent with the
deﬁnition of IGRT than ART, given that no plan revision
takes place as a result of the acquired imaging [27]. An
alternative online partial compensation for translational
and rotational anatomy change involves adjusting pre-
treatment gantry and collimator angles [51,52].
‘Plan of the day’ solution accesses a library of pre-
prepared plans selected for treatment according to best
anatomical ﬁt for that fraction [53e56]. Although no furtherPre treatment imaging In room imaging  
Beam on room imaging  
Image registration and comparison
Online adaptive plan reoptimisation
Real time reoptimisation, 
(tracking or gating)
Fig 2. Typical workﬂow of ART.
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and geometric relationship to adjacent structures are
considered in part for the library creation [57]. For example,
‘plan of the day’ for cervical cancer radiotherapy utilises
bladder ﬁlling to generate a model predicted ITV that is
then used to inform the library creation [54].
‘Virtual couch shift’ or ‘dose shift’ approach translates
and rotates the pre-treatment dose distribution (without
new contour regeneration) to compensate for the positional
changes in patient’s anatomy. An alternative plan is auto-
matically generated and delivered, producing a clinically
similar dose distribution to pre-treatment, but at the new
position [58]. This dose shift strategy is independent of any
couch limitations and is therefore an important solution for
the MRI-linear accelerator (linac) (Elekta AB, Stockholm,
Sweden), which at present does not allow table shifts [59].
Use of a deformation ﬁeld has also provided a solution
for a number of other online adaptive re-planning strategies
[60e62]. The method is essentially reliant on deriving a
three-dimensional (3D) geometrical transformational ma-
trix from the planning scan and the image of the day, and
using it to ‘morph’ the treatment plan as an online correc-
tion method. An alternative approach is to perform online
ART based on a new target outline [50]. A number of single
centres have successfully implemented online ART re-
planning workﬂows, demonstrating both feasibility and
dosimetric beneﬁt of this approach [42,60,63,64].
Acharya et al. utilising the MRIdian platform (ViewRay
Inc., Oakwood Village, OH, USA) illustrate clinical feasibility
of treating abdominal malignancies with gated motion
management and conventional fractionation. An online re-
optimisation trigger was based on maintaining pre-
determined target and OARs doseevolume histogram
(DVH) constraints when the initial plan to anatomy of the
day was fused. If the PTV dosewas inadequate or the critical
structure dose was exceeded, re-optimisation was per-
formed on the anatomy of the day. Using this criterion,
30.6% (52/170) fractions were treated with online re-
optimisation and 54.1% (92/170) fractions were treated
with either an online adapted plan or previously adapted
plan [42].
In a prospective Phase I study, stereotactic MRI-guided
online ART was used to treat primary abdominal tumours.
Initial plan performance was evaluated on the MRI ‘anat-
omy of the day’. Using this approach, 84% (81/97) fractions
were treated with online adaptation. Although the majority
of fractions (63%; 61/97) necessitated adaptation because
OARs DVH constraints would have been violated if the
initial plan had been used, in 21% (20/97) of fractions
anatomy of the day appeared favourable for dose escalation
while maintaining strict OAR constraints [65].
For primary abdominal malignancies, such as locally
advanced pancreatic cancer, the ability to dose escalate has
the potential to improve clinical outcomes [66]. Without
online MRI informed re-optimisation, radiation dose has
been limited to sub-ablative levels because of poor visual-
isation of OARs and normal tissue toxicity [67].
Simulation studies reﬂect that daily online adaptation
would also provide a dosimetric advantage at otherEnabled by MRI Guidance, Clinical Oncology (2018), https://doi.org/
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optimisation in bladder cancer radiotherapy based on
anatomy of the day is superior to both PTV with population
derived margins, i.e., no adaptation, and to ‘plan of the day’
approach. This is achieved with a decrease in PTV size and
subsequent reduction in normal bowel irradiation [40].
Similarly, in cervical cancer, online re-planning using MRI
guidance reduces the absolute volume of small bowel
receiving more than 45 Gy (V45Gy) by approximately 100
cm3 [68].
Advanced Motion Management: Gating
Any effective ART strategy is reliant on its ability to ac-
quire high-quality online images with high geometric and
temporal resolution [69,70]. The greater the delay between
imaging and treatment, the greater the opportunities for
short-term organ motion [13]. Integrated MRI-guided
platforms enable rapid high-quality imaging to take place
immediately before and during the delivery of each radio-
therapy fraction. This ‘beam-on’ imaging means motion
monitoring occurs during treatment delivery and is able to
provide opportunity for ‘real-time’ anatomical feedback to
inform adaptation. Motion blurring is reduced by speed of
MRI data acquisition.
Intrafractional motion varies according to tumour posi-
tion within the body [71,72]. Breathing motion can result in
target lesions in the lung or intra-abdominal cavity moving
several millimetres or several centimetres [73,74]. To try
and capture tumourmotion throughout the breathing cycle,
four-dimensional (4D) CT has been used to inform a per-
sonalised internal target volume (ITV). Breathing motion,
however, is often unpredictable, and single 4D CT is rarely
representative of true range of motion through treatment
and so requires application of large treatment margins to
avoid geographical miss [75e77].
Gating mitigates intrafractional motion by delivering
dose only when target is within a deﬁned geographical
position. By convention, position recognition for gating has
been reliant on either being able to see the target on CBCT,
the use of external surrogates [78], implanted radiopaque
markers [79] or electromagnetic transponders [80]. These
methods successfully improve geometric and dosimetric
accuracy compared to non-gated approaches [81].
AnMRI-gated solution provides adequate visualisation of
the target and therefore can be performed without
implanted devices or potentially unreliable external surro-
gates [82]. Gating without implanted devices or external
surrogates is currently in use within the MRIdian system
(ViewRay Inc.). Using this approach the GTV to PTV margin
has been reduced from 5 to 2 mm for stereotactic ablative
radiotherapy [63].
Advanced Motion Management: Tracking
Tracking is a technique whereby the target is ‘followed’
by the radiation beam, and treatment delivery parameters
are continually adjusted to compensate for tumour motion.
The target remains within the beams eye view at all times.Please cite this article in press as: Hunt A, et al., Adaptive Radiotherapy
10.1016/j.clon.2018.08.001Unlike gating, the treatment machine is always on and so
treatment times are expected to be comparably shorter
[83].
Tracking can be achieved in one of three ways: it is
possible to shift the treatment source to track tumour mo-
tion, to shift the beam using multi-leaf collimators (MLCs),
or adjust the patient position relative to the stationary
beam [84]. Robotic, gimballed, MLC, and couch-tracking
systems are all solutions implemented for tumour
tracking [84e86]. They rely on CT and kilovoltage image
guidance or implanted devices.
MRI-guided tracking is possible because the superior
soft-tissue deﬁnition allows easy identiﬁcation of target and
OARs deformation and rotation [87]. This is advantageous
because surrogates for tumour position have limitations in
their ability to accurately describe motion [88e90].
In a proof of concept study, it has been possible to track
motion using MLCs in combination with a fast one-
dimensional (1D) MRI sequence [83]. An MRI-guided two-
dimensional (2D) tracking solution has also been deter-
mined [90]. Although MRI-informed tracking is not yet in
clinical practice, it is expected to be possible soon. Simula-
tion work in lung cancer cases suggests when clinically
implemented, it would be expected to spare healthy tissue,
including reducing the mean lung, skin, and great vessels
dose while maintaining dose to 98% of GTV compared to
conventional dose deliveries [91]. The reported improve-
ments in normal tissue irradiation reﬂect ability to deliver
treatment using tracking on a gantry-based linac with
reduced PTV size compared to the standard ITV approach. If
this technique were to be applied for the treatment of lung
and pancreatic cancer, the PTV could be reduced by up to
40% and 17%, respectively [92,93].
Real-Time Adaptive Re-planning
Real-time ART has the potential to improve accuracy of
the delivered dose to target with normal tissue sparing,
independent of the delivery system [84]. This suggests that
each fraction should be adapted irrespective of pre-
determined action levels. Adapting the plan during beam
delivery necessitates continuous imaging with a real-time
motion management method, re-planning, and rapid dose
calculation.
The team from the University Medical Centre Utrecht
recently published a potential solution to this problem
illustrated in a proof of principle study based on their Elekta
MR-linac (Elekta AB, Stockholm, Sweden). This study de-
scribes a novel real-time adaptive treatment pathway
where intrafraction, inter-beam re-planning and optimisa-
tion takes place, taking into account the previously deliv-
ered dose within that fraction accumulated onto the
underlying moving anatomy [94].
Fast inverse IMRT re-planning based on the updated 3D
anatomy during intrafraction delivery was possible in part
because of a treatment planning method called adaptive
sequencer (ASEQ) [95]. ASEQ is an iterative process that
begins with initial optimisation that faithfully reﬂects the
ideal/prescribed dose. Each iteration produces uniqueEnabled by MRI Guidance, Clinical Oncology (2018), https://doi.org/
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segment is calculated and is subtracted from the ideal dose
distribution. The updated dose distribution then informs
the next iteration. This is repeated until dose convergence
between the delivered and prescribed dose occurs [95,96].
In the context of a single fraction (25 Gy) stereotactic
body radiotherapy (SBRT) planning study, application of
ASEQ showed that inter-beam IMRT re-planning to a no-
margin PTV had theoretical beneﬁt with higher dose
target coverage, tighter dose distributions, and improved
normal tissue sparing compared to a mid-respiratory posi-
tion SBRT plan with a 3 mm PTV margin. The high dose
region (deﬁned as 2 cm around the target) was decreased by
an average of 27.8% with real-time planning [94]. A no-
margin PTV was only feasible because MRI data were
continuously informing the 3D anatomical deformations of
the target and OARs during treatment delivery [94].Future Considerations for MRI-Guided ART
It is attractive to envision that we are entering a new era
of radiotherapy. MRI-guided ART enabled by technological
and computational advances has increased the precision of
RT with potential increase in the therapeutic window. We
would, however, advocate caution, as we are yet to
demonstrate that the dosimetric gains seenwill translate to
meaningful clinical outcomes for our patients [97].
It is certain that not all patients will derive the same
beneﬁt with ART. Prospective evaluation within a robust
framework is necessary [98,99]. Well-designed clinical tri-
als remain the optimal method to evaluate patient beneﬁt of
this technology; however, head-to-head comparative
studies of CT-guided and MRI-guided ART using standard
dose and fractionations delivered to an anatomical target
may not be ambitious enough to demonstrate the true po-
tential of MRI-guided technology in terms of improved
toxicity, local control, and survival. Many groups are
investigating how MRI-guided ART provides a platform to
deliver radiation in circumstances that would have other-
wise been impossible. These include ultra-
hypofractionation (single radical fraction) in regions of or-
gan motion [100], safer re-irradiation [101], and integrating
on-board functional MRI sequences to inform biological
feedback for personalised adaptation [102]. The future of
ART will be MRI guided, but how we choose to best apply
this tool in order for it to be measurably transformative for
patient outcomes remains to be determined.
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